載入...
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
IMPORTANCE: The US Food and Drug Administration’s (FDA’s) accelerated approval pathway allows investigational cancer drugs to be approved by demonstrating a beneficial effect on a surrogate measure (eg, progression-free survival) that is expected to predict a real clinical benefit (eg, overall survi...
Na minha lista:
| 發表在: | JAMA Intern Med |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Medical Association
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6547118/ https://ncbi.nlm.nih.gov/pubmed/31135808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2019.0462 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|